1. Academic Validation
  2. Discovery and Evaluation of Pyrazolo[3,4- d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor

Discovery and Evaluation of Pyrazolo[3,4- d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor

  • ACS Med Chem Lett. 2019 Dec 11;11(10):1863-1868. doi: 10.1021/acsmedchemlett.9b00395.
Xuejun Zhang 1 2 Xijun Sheng 1 2 Jie Shen 1 2 Shoubo Zhang 1 2 Wenjie Sun 1 2 Chunli Shen 3 Yi Li 3 Jun Wang 3 Huqiang Lv 3 Minghui Cui 3 Yuchuan Zhu 3 Lei Huang 3 Dongling Hao 3 Zhibo Qi 3 Guanglong Sun 3 Weifeng Mao 3 Yan Pan 3 Liang Shen 3 Xin Li 3 Guoping Hu 3 Zhen Gong 3 Shuhua Han 3 Jian Li 3 Shuhui Chen 3 Ronghua Tu 1 2 Xuehai Wang 2 Chengde Wu 3
Affiliations

Affiliations

  • 1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., No. 666 High Tech Avenue, East Lake High Tech Development Zone, Wuhan, Hubei 430075, China.
  • 2 Humanwell Healthcare (Group) Co., Ltd., No. 666 High Tech Avenue, East Lake High Tech Development Zone, Wuhan, Hubei 430075, China.
  • 3 Domestic Discovery Service Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Abstract

The identification and lead optimization of a series of pyrazolo[3,4-d]pyridazinone derivatives are described as a novel class of potent irreversible Btk inhibitors, resulting in the discovery of compound 8. Compound 8 exhibited high potency against Btk kinase and acceptable PK profile. Furthermore, compound 8 demonstrated significant in vivo efficacy in a mouse-collagen-induced arthritis (CIA) model.

Figures
Products